Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (15416)	6/23/2001 10:08:11 AM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Now you love the TSC!!! Biogen is right, Amevive is great, anallist wrong, and This renew Biogen investor is even happier. Amevive 21% response at 14 weeks, 33% at 24 weeks (xanelim subjects are roaring back, at best, by 24 weeks). Biogen is THE leader, Amevive will be in the market early next year, xomadna will be just waiting for April02 data, out in 2004 at best. Monday comes the realization of how behind xoma is and back to a more reasonable $10 (my wish, not my prediction)JOL.